Gossamer Bio Secures Up to $250M in Structured Financing for Seralutinib FDA Push — Gossamer Bio, Inc.

Event summary

Gossamer Bio raises up to $250M in structured private placement, including $150M committed capital contingent on FDA NDA acceptance for seralutinib.
Initial $25M closing expected August 24, 2026, with additional $125M contingent on 2026 NDA acceptance milestone.
Financing includes warrants exercisable upon FDA approval, potentially adding $100M in gross proceeds.
Proceeds will fund seralutinib development through potential FDA approval and into 2028 operations.
Investors include EcoR1 Capital, 683 Capital Partners, RA Capital Management, and others.

The big picture

Gossamer Bio's $250M financing underscores the high-stakes nature of bringing seralutinib to market, aligning capital deployment with critical regulatory milestones. The structured approach reflects both the opportunity and risk in the pulmonary hypertension treatment space, where successful FDA approval could position Gossamer as a key player. The involvement of prominent healthcare investors signals confidence in the seralutinib program's potential, but the contingent nature of the funding highlights the regulatory hurdles ahead.

What we're watching

Regulatory Milestones: Whether the FDA will accept the seralutinib NDA in 2026 as planned, triggering the second closing of $125M.
Execution Risk: The pace at which Gossamer can advance seralutinib through FDA approval and potential commercialization.
Market Dynamics: How the structured financing model will impact investor confidence and Gossamer's valuation.